The analysis comparing the prognostic value of inflammation markers in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors demonstrates that host immune markers could be valuable predictors of clinical outcome. The neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive protein provide additional information about patient status and might be helpful in improving the treatment individualization. Background: Inflammation plays a crucial role in cancer development. In this study, we evaluate the prognostic values of systemic inflammation markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) for the progression-free survival and overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Materials and Methods: PubMed and the Cochrane Library databases were searched for published studies on the effect of NLR, PLR, and CRP in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Results: In the meta-analysis, NLR (hazard ratio [HR], 2.01; 95% confidence interval [CI], 1.27-3.18; P ¼ .003) and PLR (HR, 6.96; 95% CI, 5.04-9.62; P < .001) had a significant influence on progression-free survival, whereas all considered proinflammatory markers had a significant impact on overall survival: NLR (HR, 2.14; 95% CI, 1.67-2.73; P < .001), PLR (HR, 14.67; 95% CI, 11.10-19.57; P < .001), and CRP (HR, 1.96; 95% CI, 1.26-3.05; P ¼ .003). Conclusions: Inflammation markers such as NLR, PLR, and CRP are predictors of clinical outcome and could provide additional information to individualize treatment.
Introduction
A tumor is formed from cancer cells and a specific microenvironment that consists of microvessels, fibroblasts, endothelial cells, an extracellular matrix, and a complex of both innate and adaptive immune cells. An important feature of the tumor is also hypoxia. Immune components and hypoxia play a crucial role in tumor development and clinical outcome; however, the functions of the different subsets of the microenvironment have not been precisely explained.
Almost 60% to 70% of cases of clear-cell renal cell carcinoma, which is the most common kidney cancer subtype, are characterized by alterations of the Von Hippel-Lindau (VHL) tumor suppressor gene. Inactivation of the VHL leads to accumulation of hypoxiainducible factor, which influences the transcription of genes important to the survival and hypoxic response of tumors, including vascular endothelial growth factor (VEGF). 1 There is evidence that hypoxia-inducible factor may also be involved in the tumor microenvironment creation because animates the production and secretion of chemokines and chemokine receptors that accelerate myeloid cell (monocytes/macrophages, neutrophils, and dendritic cells) recruitment into tumors. 2 Likewise, hypoxia may contribute to creating tumor-derived inflammation by reinforcing the production of proinflammatory cytokines in VHL-deficient renal cell cancer (RCC) cells, which invigorate invasion of cancer cells. 3 Investigators detected also that patients with RCC have high concentration of interleukin 6 (Il-6) and interleukin in the plasma. Il-6 can promote tumour growth, and Il-8, which is one of the chemotactic factors, may induce systemic inflammation that causes changes in circulating white blood cells and platelet count as well as changes in the level of C-reactive protein (CRP). [4] [5] [6] Progress in the knowledge about the cancerogenesis has led to the discovery of antitumor therapy, such as tyrosine kinase inhibitors (TKIs). TKIs (sorafenib, sunitinib, pazopanib, axitinib) block, inter alia, VEGF receptors, as well as stem cell factor receptor (c-KIT) and fms-51 like tyrosine kinase-3 (Flt3), which are expressed on hematopoietic stem cells and precursor cells as well as mature immune cells. [7] [8] [9] The clinical course of metastatic RCC (mRCC) varies in individual patients; therefore, investigators search for prognostic factors to assess the patient's individual risk and predict the response to the therapy. The most frequently used risk models include Karnofsky performance status (PS), hemoglobin level, time from diagnosis to treatment, corrected calcium level, serum lactate dehydrogenase level, and platelet and neutrophil levels. 10 There is also evidence that potential markers of systemic inflammatory response, such as the neutrophil-to-lymphocyte ratio (NLR), defined as the absolute neutrophil count divided by the absolute lymphocyte count, as well as the platelet-to-lymphocyte ratio (PLR), defined as the absolute platelet count divided by the absolute lymphocyte count, the monocyte-to-lymphocyte ratio (MLR), defined as the absolute monocyte count divided by the absolute lymphocyte count, Creactive protein (CRP), and eosinophils, may be predictors of clinical outcome in patients with mRCC treated with TKIs. [11] [12] [13] [14] [15] These markers are inexpensive to test, are routinely performed in the clinical setting, and seem to be helpful in improving the individualization of TKI treatment, but the data about their prognostic values are limited. Thus, we conducted a systematic analysis of published studies in order to verify if systemic inflammatory response is connected with the clinical course of the disease.
Methods

Search Strategy
Studies were searched for using the terms 'C reactive protein,' 'monocyte,' 'lymphocyte,' 'platelet,' 'neutrophil,' 'NLR,' 'PLR,' 'MLR,' and 'kidney cancer' in the title and the abstract. The databases were searched for studies published between April 2005 and July 2017. We began the quest of relevant articles in 2005 because the enrollment into a phase III clinical study that confirmed the effectiveness of sorafenib was closed then. 16 We also examined the references in the analyzed articles in order to obtain additional information. Disagreements were resolved by discussion between the 2 reviewers (A.S.W. and A.L.).
Selection Criteria
Studies were recognized as eligible for analysis if they (1) were written in English, presenting data from prospective as well as retrospective clinical studies; (2) included patients of any gender aged 18 years with mRCC treated with TKIs, such as sunitinib, sorafenib, or pazopanib in first line; (3) analyzed the potential prognostic and/or predictive value of the immune status marker on clinical outcome in the form of PFS and/or OS in patients treated with TKI; and (4) were published as original articles (no abstracts, case reports, case series, reviews, meta-analyses, comments, letters, or editorials). We included in the analysis only the most relevant studies if several articles were based on the same patient material. In addition, we excluded studies that analyzed the outcome in patients with mRCC treated with everolimus or temsirolimus and studies that assessed the connection between immune status and outcome after surgical treatment. Previous immunotherapies were allowed. Additionally, only studies reporting eligible data relating to PFS and OS hazard ratios (HRs) were included in the meta-analysis.
Statistical Analysis
Each included study was searched to obtain HRs of investigated markers predicting PFS and OS in TKI-treated patients with mRCC. Random effects meta-analyses including subgroup analysis were performed to calculate estimated PFS and OS HRs. Results were shown in forest plot graphs. HR greater than 1 indicated a prognostic role of the elevated marker in shortening PFS or OS. Heterogeneity was calculated in Q analysis with I 2 estimation. A P-value < .05 was considered statistically significant. If heterogeneity was significant, meta-regression analyses were conducted to investigate factors significantly influencing HR. Statistical analyses were performed using STATISTICA version 12 (StatSoft Inc, Poland) software.
Results
Literature Search
We identified 681 potentially relevant published articles, and then we analyzed the title and the abstract according to the criteria described in the 'Selection Criteria' section, and included a total of 59 articles for evaluation. After assessing the full text, we excluded 38 articles. Finally, 20 retrospective studies and 1 phase II clinical trial were included in the analysis (Figure 1) . We analyzed 13 studies about NLR, 4 studies about PLR, and 6 studies about CRP. Some studies were appropriate for both NLR and PLR analyses. None of the studies that analyzed the MLR fulfilled the inclusion criteria. Ultimately, 13 of the 21 primary included studies were used in the meta-analysis.
Association in Systemic Inflammatory Markers Level and Clinical Outcome
NLR, PLR, and CRP have been recognized as potential markers of systemic inflammatory response that could be associated with clinical outcome in patients with mRCC treated with TKIs. A high pretreatment NLR, PLR, or CRP level was connected with shorter median PFS and OS compared with a low level of markers (Table 1) , and the difference was clinically significant. 12, 13, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] NLR may be used to predict the response to the therapy in e686 -Clinical Genitourinary Cancer June 2018
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clear-cell RCC and may also be useful in predicting the clinical outcome in patients with chromophobe mRCC treated with sunitinib. 29 Cutoffs of NLR in the included studies varied from 2 to 4; however, all investigators found significant differences in the outcome between patients with high and low baseline NLR levels. Patients with low baseline NLR treated with sunitinib achieve longer PFS and OS more often than patients with a high baseline NLR level. 18, 20 Moreover, Cetin et al showed that progression in the first 3 months after mRCC therapy initiation was connected with a higher pretreatment NLR level than progression after 3 months. 17 Investigators also detected that clinical outcome is associated not only with the pretreatment NLR level but also the reduction of the NLR level after TKI treatment, which may be a predictor of the efficacy of the therapy. 30, 31 There is evidence that patients with a lower posttreatment NLR level have a tendency toward better tumor response, and Park et al assume that posttreatment NLR might be a better prognostic factor than the pretreatment NLR level. 31 In the studies from Park et al and Dirican et al, the baseline NLR status was significantly associated with the Memorial Sloan Kettering Cancer Center (MSKCC) risk group status; however, the dependence was not confirmed in the study from Santoni et al. 18, 22, 31 The PLR level was significantly associated with PFS in multivariate analysis, but no significant relation between PLR and OS in multivariate analysis was found by Gunduz et al. 12 Likewise, Chrom et al reported that PLR > 150 and PLR > 200 were associated with a worse prognosis only in univariable analysis. 24 These effects contradict the results obtained by Park et al, who found a significant association between PFS and OS in multivariable analysis. Additionally, in the study by Park et al, in contrast to other studies, PLR, not NLR, was an independent prognostic factor for PFS and OS. 23 This difference may be partly explained by the more adequate method (the receiver operating characteristic curve) that was used to find the cutoff point value of the marker.
Patients with high levels of CRP obtained small gains from the TKI treatment 13, [26] [27] [28] 32, 33 ; however, in the study from 
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Clinical Genitourinary Cancer June 2018 -e687 Kobayashi et al, the CRP level was not a significantly important factor for OS prediction in univariate analysis. 30 In the study from Bauselinck et al, patients with a normal baseline CRP level had a partial or complete response more frequently than patients with an elevated pretreatment CRP level. 27 Similar results were obtained by Kawai et al. 28 Moreover, patients with a normalized CRP level during sunitinib treatment tend to achieve clinical benefits more frequently. 28 Fujita et al reported that all patients with a low CRP level had a favorable or intermediate forecast according to MSKCC risk classification, and patients with high CRP were classified into the poor cohort. 13 A high pretreatment CRP level may also be connected to the outcome, regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score, and patients in the poor risk group with a correct CRP level had a better prognosis compared with patients in the favorable risk group with a high baseline CRP level. 26 
Risk Factors Associated With Outcome
The impact of host immune status markers on OS was also assessed in connection with prognostic factors according to the MSKCC or the IMDC classifications (Table 2) . 23, 24, 26, 27, 32, 34 The performed analyses demonstrated that NLR, PLR, and CRP, similarly to presently used markers, are important and independent factors that influence outcome.
Progression-Free Survival
Meta-analysis with a random effect model of eligible studies 12, [17] [18] [19] [20] [21] [22] [23] 27, 28, 32 showed a significant association between the activity of the immune system and clinical outcome. Patients with high values of the considered markers have shorter PFS (HR, 2.96; 95% CI, 2.20-3.99; P < .001). Heterogeneity among the investigated studies was significant (I 2 ¼ 94.81%; P < .001). In metaregression analysis, the cutoff point value was essentially related to HR (R 2 ¼ 67.61%; P < .001). Moreover, studies referring CRP (P ¼ .022) and PLR (P < .001) showed a significant influence on estimated HR (R 2 ¼ 9.22%; P < .001). When studies were divided into 3 groups according to the considered marker, only NLR (HR, 2.01; 95% CI, 1.27-3.18; P ¼ .003) and PLR (HR, 6.96; 95% CI, 5.04-9.62; P < .001) had a significant influence on PFS (Figure 2 ). Higher values of CRP insignificantly elevated the risk of PFS shortening (HR, 1.69; 95% CI, 0.95-3.01; P ¼ .074). In comparison analysis of HR values, the NLR and CRP groups did not differ significantly, but both were lower than PLR (P < .001).
Overall Survival
Meta-analysis with a random effect model of the association of pretreatment markers 12 (Figure 3 ). Comparison of HR values revealed no differences between the NLR and CRP groups and a substantially higher value of HR in the PLR group compared with the NLR (P < .001) and CRP (P < .001) groups. TKIs, such as sorafenib, sunitinib, and pazopanib, are first-line treatment for most patients with mRCC; however, the response to the therapy differs between individual patients. Currently available prognostic scores achieve a concordance of 0.68 to 0.89 for cancer-specific survival and 0.74 to 0.82 for recurrence-free survival, 10 so new factors are necessary to improve the prediction of the response to therapy. Our study indicates that host immune status markers, such as NLR, PLR, and CRP, could be valuable factors
Figure 2 Meta-analysis of the Association of Pretreatment Markers on Progression-free survival
Abbreviations: CI ¼ Confidence interval; CRP ¼ C-reactive protein; HR ¼ hazard ratio; NLR ¼ neutrophil-to-lymphocyte ratio; PLR ¼ platelet-to-lymphocyte ratio.
Figure 3 Meta-analysis of the Association of Pretreatment Markers on Overall survival
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that give new information about the patient's individual risk. In this meta-analysis, we detected that NLR and PLR had a significant impact on PFS, and all considered markers are significant prognostic factors of OS. Combining 3 different markers in 1 meta-analysis was a cause of significant and prospective heterogeneity. This was confirmed in meta-regressions, in which different cutoff points and markers had a significant influence on pooled HR values. These differences enabled subgroup analyses, and comparison of marker-specific HR values revealed that PLR is substantially better at outcome prediction than NLR and CRP. However, only 2 studies about PLR were relevant for analysis, and in one of them, the cutoff point value was appointed by the receiver operating characteristic curve. 23 In the other study, the cutoff point represented the point at which the survival difference between the analyzed groups was maximized, 12 whereas most studies included in the meta-analysis did not justify their cutoff points.
Tumor Microenvironment and Systemic Inflammation
Proinflammatory factors are considered as potential markers for the outcome of patients with cancer because inflammation associated with the tumor has a great influence on the development of cancer, its progression, and its response to the administered therapy. Tumor development is a result of genetic alterations in cells as well as the presence of cytokines produced by microenvironment components and activation of some transcription factors (inter alia, activator protein 1 [AP-1], nuclear factor kappa-light-chain-enhancer of activated B cells [NF-kB], signal transducers and activators of transcription [STAT3]) that are also essential for inflammation development. 1, 4 Tumor-associated macrophages coming from monocytes promote development of neoplasm by production of tumor-promoting cytokines such as Il-6 and proangiogenic factors (ie, VEGF), and they enhance recruitment of immune cells into the tumor. 4, 36 A significant component of the tumor microenvironment is tumor-infiltrating lymphocytes, which promote antitumor response by cytotoxic-and humoral-mediated immune responses; however, there is also evidence that these cells may be involved in tumor development. Important element of tumor microenvironment makes myeloid-derived suppressor cells (MDSCs) that tone immune responses so promote cancer development. Neutrophils that colaborate the tumor microenvironment take part in extracellular matrix degradation and stimulation of expression of adhesion molecules that enhance the attachment of circulating metastatic cells to hepatic sinusoids. 4, 36, 37 Proinflammatory cytokines, such as IL-6, IL-8, the granulocytemacrophage colony-stimulating factor, and tumor necrosis factor-a produced by microenvironment components of tumor and RCC cells with Myc amplification, could participate in the activation of immune cells, mainly neutrophils which can promote destruction of tumor cells; however, a high neutrophil level in patients with cancer was reported as an independent factor of poor prognosis, which might be caused by the above-mentioned secretion of matrixdegrading enzymes that promote tumor development. 4, [38] [39] [40] A characteristic feature of systemic inflammation is lymphocytopenia, which expresses the decline in T-lymphocytes and the depression of cell-mediated immunity caused by increased margination, redistribution, and apoptosis of lymphocytes induced by cytokines and chemokines. 41 Investigators have found that T cell proliferation could also be handicapped by RCC cells with a VHL mutation. 42 The immune response to stress factors such as pathogens or tumors is expressed by the changes in neutrophil and lymphocyte levels, but the ratio of neutrophil counts to lymphocyte counts could be a more effective factor in patients with cancer. 18, 19, 22, 24, 41 Nevertheless, the knowledge about the role of peripheral neutrophils and lymphocytes in patients with RCC is relatively small, and future studies are needed to precisely explain the connection between immune cells and tumor cells.
Increased levels of proinflammatory cytokines also stimulate trombopoesis. Platelets have been considered mainly as regulators of hemostasis; however, it is clear that they have multiple functions in inflammation and immunity. Stimulated platelets release peptides that include growth factors and chemotactic factors that are, inter alia, substantial mediators in the recruitment and activation of Figure 4 Evidence Profile of Individual Studies Included to the OS meta-analysis (GRADE) 47 Abbreviations: CI ¼ Confidence interval; CRP ¼ C-reactive protein; HR ¼ hazard ratio; NLR ¼ neutrophil-to-lymphocyte ratio; OS ¼ overall survival; PLR ¼ platelet-to-lymphocyte ratio.
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Clinical Genitourinary Cancer June 2018 -e691 leukocytes. 43, 44 There is also evidence that platelets may protect cancer cells from NK-cell-mediated killing, 4 but the role in cancer is unclear. Further research is needed to better understand the function of platelets in the development of cancer. CRP is a protein produced by the liver as a consequence of the changes in the concentrations of inflammatory-associated cytokines in plasma. 45 A main function of CRP is the recognition of foreign pathogens and damaged cells, and, subsequently, the activation of innate immune system mechanisms that eliminate targeted cells by humoral and cellular effector systems of inflammation. An elevated CRP level in patients with cancer who exhibit a high level of inflammatory-associated cytokines produced by the tumor may be a predictor of a more extended and more aggressive disease. Researchers have found that patients with mRCC with increased CRP levels had more metastatic sites and a poorer IMDC score. 26 In the present work, we found a significant influence of high values of NLR and PLR on PFS as well as NLR, PLR, and CRP on OS shortening. Our results are in accordance with data published by Na et al. 46 In fact, one of the most important prognostic and predictive factors is PS. Patients with a worse Eastern Cooperative Oncology Group PS have worsened clinical symptoms of cancer and tolerate treatment with difficulty, so they have poorer outcomes compared with patients with a better PS. However, the assessment of PS is based on the subjective opinion of the patient or his family about daily activities; therefore, using PS as a prognostic parameter may be inadequate. NLR, PLR, and CRP exhibit the activity of the immune system and the dependence between their components, and thus these markers could provide additional information. Moreover, NLR, PLR, and CRP, similarly to hemoglobin level or lactate dehydrogenase level, are objective and easily measurable parameters, and according to Maruzzo et al, may be connected with the tolerance of sunitinib, the impact of the cumulative dosage of the drug during treatment, and, indirectly, the survival outcomes in the form of PFS and/or OS. 25 The posttreatment NLR level also resulted from the clinical outcome. 30, 31 This dependence suggests the usefulness of assessment of the NLR level in patients before therapy modifications owing to, for example, side effects. There are no precision data that allow using the NLR, PLR, or CRP level in the choice of treatment scheme, so future prospective studies are necessary to validate the results of the retrospective studies.
To the best of our knowledge, this is the largest review to analyze the host immune status as a prognostic factor in patients with mRCC treated with TKIs. Our study indicates that NLR, PLR, and CRP, similarly to prognostic factors according to the MSKCC or IMDC classifications, are valuable markers; however, they provide information about host immune status that is engaged in the clinical course of the disease so they enable tighter assessment of the patient's individual risk. We also performed a comparison of markerspecific HR values and detected that PLR could be better at outcome prediction than NLR and CRP. Furthermore, we tried to explain the association between the immune system and cancer course and cancer treatment, but the knowledge about analyzed dependences is relatively small, requiring further studies.
There are several limitations in our study. First, we used retrospective data with a relatively small sample size, which may have interfered with our survival analyses. In addition, the analyses contain only those studies that report relevant information. Despite the quality of the evidence included to the meta-analyses studies being moderate to high, our study is based on data reported by other authors, so precise analysis of which marker is the best to predict the clinical outcome was impossible (Figure 4) . 47, 48 Survival analysis was also disturbed by lack of detailed information regarding treatment after TKI progression, which could be important for received results. Moreover, neutrophil and lymphocyte counts and CRP level are nonspecific parameters, which may be influenced by concurrent conditions such as infections or medications. However, the included studies reported NLR, PLR, and CRP received before the start of systemic therapy in which acute infections have to be excluded. Nevertheless, the confounding effect of concurrent conditions cannot be ignored.
Conclusions
NLR, PLR, and CRP, as representative markers of host immune status, allow prediction of the clinical outcome in patients with mRCC treated with TKIs. Assessment of these markers might also provide additional information before treatment modification. NLR, PLR, and CRP are simple and easily available biomarkers and could be useful in improving the individualization of TKI treatment in patients with mRCC. However, further prospective studies on large cohorts are warranted to validate the knowledge.
Clinical Practice Points
The clinical course of mRCC varies in individual patients, and currently available prognostic scales do not allow specification of the response to therapy. Systemic inflammatory markers are useful in the prediction of the clinical outcome in patients with mRCC treated with TKIs. NLR, PLR, and CRP provide additional information about patient status and might be helpful in improving the individualization of TKI treatment in patients with mRCC.
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